ALLOVIR, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8065 USD | -0.43% |
|
+0.81% | +18.64% |
| Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
| Mar. 15 | AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 90.05M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | -41M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 129M | Net cash position 2025 * | 220M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-2.28
x | Employees | 112 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on AlloVir, Inc.
More recommendations
More press releases
| 1 day | -0.43% | ||
| 1 week | +0.81% | ||
| Current month | +1.52% | ||
| 1 month | +5.08% | ||
| 3 months | +16.13% | ||
| 6 months | -53.91% | ||
| Current year | +18.64% |
1 week
0.77
0.82
1 month
0.710.83
Current year
0.620.85
1 year
0.626.12
3 years
0.6226.41
5 years
0.6248.96
10 years
0.6248.96
| Managers | Title | Age | Since |
|---|---|---|---|
Juan F. Vera
FOU | Founder | 44 | 13-07-31 |
Ann M. Leen
FOU | Founder | 47 | 13-07-31 |
Diana Brainard
CEO | Chief Executive Officer | 53 | 19-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vikas Sinha
PSD | President | 60 | 18-08-31 |
| Director/Board Member | 57 | 19-04-30 | |
David Hallal
CHM | Chairman | 57 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% | ||
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 0.8065 | -0.43% | 147,565 |
| 24-05-01 | 0.81 | +1.96% | 222,123 |
| 24-04-30 | 0.7944 | -2.47% | 181,229 |
| 24-04-29 | 0.8145 | +2.18% | 171,837 |
| 24-04-26 | 0.7971 | -0.36% | 199,202 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
5
Last Close Price
0.8065
USD
Average target price
1
USD
Spread / Average Target
+23.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.64% | 90.44M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
- Stock Market
- Equities
- ALVR Stock
